Abstract:Abstract Purpose Diffuse intrinsic pontine glioma (DIPG) bears a dismal prognosis. A genetically engineered brainstem glioma model harboring the recurrent DIPG mutation, ACVR1-G328V (mACVR1), was developed for testing an immune-stimulatory gene therapy. Experimental Design We utilized the Sleeping Beauty transposase system to generate an endogenous mouse model of mACVR1 brainstem glioma. Histology was used to characterize and validate the model. We performed RNAseq analysis on neurospheres (NS) harboring mACVR1. mACVR1 NS were implanted into the pons of immune competent mice to test the therapeutic efficacy and toxicity of immune stimulatory gene therapy using adenoviruses expressing thymidine kinase (TK) and fms-like tyrosine kinase 3 ligand (Flt3L). mACVR1 NS expressing the surrogate tumor antigen ovalbumin were generated to investigate if TK/Flt3L treatment induces the recruitment of tumor-antigen specific T cells. Results Histological analysis of mACVR1 tumors indicates that they are localized in the brainstem and have increased downstream signaling of bone morphogenetic pathway as demonstrated by increased phospho-smad1/5 and Id1 levels. Transcriptome analysis of mACVR1 NS identified an increase in the transforming growth factor beta (TGF-β) signaling pathway and the regulation of cell differentiation. Adenoviral delivery of TK/Flt3L in mice bearing brainstem gliomas resulted in anti-tumor immunity, recruitment of anti-tumor specific T cells and increased median survival. Conclusions This study provides insights into the phenotype and function of the tumor immune microenvironment in a mouse model of brainstem glioma harboring mACVR1. Immune stimulatory gene therapy targeting the hosts’ anti-tumor immune response inhibits tumor progression and increases median survival of mice bearing mACVR1 tumors. Translational Relevance The therapeutic efficacy of anti-DIPG immune responses is limited due to a low number of immune cells in the tumor microenvironment. We have uncovered a novel treatment strategy that utilizes adenoviral delivery of therapeutic genes, thymidine kinase (TK) and fms tyrosine kinase 3 ligand (Flt3L) into the tumor, eliciting a reprograming of the host’s own immune system to recognize and kill tumor cells. We demonstrate that TK/Flt3L therapy generates an effective anti-tumor response and can be safely delivered into the brainstem. This treatment approach could provide a novel translational approach towards potentiating an anti-DIPG immune response to overcome the current limitations in the treatment of patients with DIPG.

Targeted Gene Therapy Toward Astrocytoma Using a Cre/loxP-based Adenovirus System.

Gene Therapy with HSV1-sr39TK/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK/GCV in Rat C6 Glioma Cells

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters.

Noninvasive Delivery of Adenoviral-Mediated Suicide Gene to Treat Glioma Through Focused Ultrasound-Induced BBB Opening

Combined IL-2/IL-3 Gene Therapy of Glioblastoma by in Situ Injection of Recombinant Adenovirus

Tumor-specific transcriptional targeting of suicide gene therapy

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

In Vivo Replication-Deficient Adenovirus Vector-Mediated Transduction of the Cytosine Deaminase Gene Sensitizes Glioma Cells to 5-Fluorocytosine.

Improved Adeno-associated Viral Gene Transfer to Murine Glioma.

Adeno‐associated virus (AAV)-based gene therapy for glioblastoma

Glioma Stem Cells Targeted by Oncolytic Virus Carrying Endostatin–angiostatin Fusion Gene and the Expression of Its Exogenous Gene in Vitro

Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem glioma

Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease

Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk

To Cross the Blood–Brain Barrier and Treat Murine Glioma

Combination Effect of Oncolytic Adenovirus Therapy and Herpes Simplex Virus Thymidine Kinase/ganciclovir in Hepatic Carcinoma Animal Models.

Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma

Preclinical gene therapy in glioblastoma multiforme: Using olfactory ensheathing cells containing a suicide gene

Gene Therapy Targeting Hepatocellular Carcinoma by A Dual-Regulated Oncolytic Adenovirus Harboring the Focal Adhesion Kinase Shrna

Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration.